My research group works on molecular pathology, genetics and progression of leukaemia and lymphomas, aiming to improve on current diagnostic, prognostic and treatment strategies.
My group is interested in epigenetic regulation of somatic mutagenesis in normal and malignant B cells. We aim to understand how alterations in the nuclear envelope influence B cell chromatin conformation, and what the epigenetic consequences of these alterations are.
My group works on developing novel approaches to improve efficacy and safety of allogeneic stem cell transplantation and adoptive immunotherapy as treatments for blood cancers. We focus on T-cell alloreactivity in the context of stem cell transplantation and immunotherapy.
My research interests focus on mechanisms of disease initiation and maintenance and the identification and validation of novel therapeutic targets in myeloid leukaemias.
Our goal is to identify mechanisms that support haematopoietic stem cell function and understand how the leukaemic stem cells “play” with these mechanisms to thrive.
My primary research interests include the immunotherapy of cancer (including stem cell transplantation), the identification of B-cell-tumour antigens; and the detection and treatment of minimal residual disease in leukaemia and lymphoma.
Our research aims to understand the biology of leukaemia stem cells and identify tricks they use to escape treatments. My group employs multidisciplinary approaches to understand how HSCs chose to self-renew or differentiate and how these cell fate decisions are affected under pathological conditions to generate leukaemic stem cells.
My studies concentrate on the immunogenetics of human B cell malignancies, such as chronic lymphocytic leukaemia, follicular lymphoma and the role for B cell receptor in the development of B cell lymphoma and leukaemia.
I am the Module Lead for 3 undergraduate Biomedical Science Modules. I am also the Cancer Theme Lead for MBBS with direct responsibility for Year 2 Cancer Week. In addition, I supervise MSc project dissertations.
My research focuses on understanding the genetic and molecular mechanisms that underlie the initiation and progression of B-cell non-Hodgkin’s lymphomas in order to define clinically-relevant biomarkers.
My major research interest is understanding the metabolism of chronic lymphocytic leukaemia and lymphoma with the aim that this will underpin the development of the next generation of anti-metabolic drugs for these diseases.
My main research interests are in haematopoietic stem cells (HSCs) and leukemic initiating cells. I seek to understand how intrinsic and extrinsic signals are integrated by normal and malignant stem cells.
My research focuses on the fundamental aspects of leukaemia initiating cell (LIC) biology in adult acute lymphoblastic leukaemia, with the aim of gaining fundamental insight into the underlying biology of LICs to reveal dependencies that are tractable targets for therapy.
The aim of my research project is to identify and functionally characterise candidate disease genes in familial leukaemia.
My work is currently focused on lymphoma, working on variant calling and gene expression analysis of NGS data.
My work is based on studying signalling networks in AML primary samples in order to predict responses to kinase inhibitors.
My research is focused on describing the mechanisms underlying Lamin B1 nuclear disassembly in B-cell normal development and how a dis-regulated Lamin B1 removal pathway could lead to several haematological malignancies within the germinal centre in secondary lymph organs.
My research focuses on the fundamental aspects of leukaemia initiating cell biology in adult acute lymphoblastic leukaemia.
Our work aims to better understand aneuploidy tolerance in cancer, in particular with regard to monosomy in AML.
My project focuses on the translation reprogramming in acute myeloid leukaemia upon stresses such as chemotherapy.
My research project aims to identify germline mutations in families with leukaemia of unknown aetiology and study the intra and inter leukaemia heterogeneity observed in these families, through examination of clonal evolution and secondary genetic events.
My research involves using mass cytometry based analysis to characterise the interaction, activation, and signalling capacity of B and T-cells in CLL and other B-cell malignancies.
I use computational biology techniques to understand how normal RNA regulatory mechanisms used in development are hijacked in cancers.
My project looks at the metabolic mechanisms of drug resistance in acute myeloid leukaemia (AML). We look to understand what makes certain cells more vulnerable to AML treatment and how we can use this to improve overall treatment strategies.